Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer When BCG Therapy Has Failed
This protocol addresses BCG-unresponsive high-risk non-muscle-invasive bladder cancer — a distinct clinical situation that arises when standard intravesical BCG therapy does not achieve the expected disease-control milestones.
Clinical scenario
The high-risk NMIBC group covered here includes T1 high-grade/G3 tumours without carcinoma in situ, isolated carcinoma in situ, and lower-stage presentations (Ta LG/G2, T1 G1, Ta HG/G3, T1 LG, T1 G2) that meet defined additional risk thresholds — age over 70, multiple tumours, or tumour diameter over 3 cm — in the absence of CIS. The scenario specifically excludes carcinoma in situ in the prostatic urethra, lymphovascular invasion, and aggressive urothelial carcinoma subtypes.
Prior treatment: BCG — failure condition
First-line management for this group consists of transurethral resection of bladder tumour followed by full-dose intravesical BCG therapy. Escalation to this protocol is indicated when BCG has not met its primary goals:
- Persistent high-grade tumour on cystoscopy at 3 months
- Carcinoma in situ on bladder biopsy at 6 months
- Positive urine cytology for high-grade urothelial carcinoma
Disease that meets these criteria is classified as BCG-unresponsive. Further BCG therapy is unlikely to achieve a response at this point.
Next-step treatment approach
Radical cystectomy is the standard and preferred treatment for BCG-unresponsive high-risk NMIBC. For patients who are not candidates for cystectomy due to comorbidities, or who decline it, bladder-preservation strategies — involving both intravesical and systemic modalities — are available, though these are considered oncologically inferior. The full protocol details the specific options and the criteria guiding their selection.
Treatment goals
- No bladder tumour on cystoscopy at 3 months
- Complete response of carcinoma in situ on bladder biopsy
- Negative urine cytology for high-grade urothelial carcinoma
References
- All T1 HG/G3 without CIS, EXCEPT those included in the very high-risk group.
- All CIS patients, EXCEPT those included in the very high-risk group.
- Ta LG/G2 or T1 G1, no CIS with all three risk factors.
- Ta HG/G3 or T1 LG, no CIS with at least two risk factors.
- T1 G2 no CIS with at least one risk factor.
- Offer an RC to patients with BCG-unresponsive tumours.
- Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option.
- Offer patients with BCG-unresponsive tumours, who are not candidates for RC due to comorbidities, or who decline RC, preservation strategies (intravesical chemotherapy, chemotherapy and microwave-induced hyperthermia, electromotive administration of chemotherapy, intravesical- or systemic immunotherapy; preferably within clinical trials).
- Treatments other than RC must be considered oncologically inferior in patients with BCG-unresponsive tumours.
- The first cystoscopy after TURBT at three months is an important prognostic indicator for recurrence and progression.
View source ↗